- Home
- TYRA vs ABSI Comparison
TYRA vs ABSI Comparison
Compare TYRA & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- ABSI
- Stock Information
- Founded
- TYRA 2018
- ABSI 2011
- Country
- TYRA United States
- ABSI United States
- Employees
- TYRA N/A
- ABSI N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- TYRA Health Care
- ABSI Health Care
- Exchange
- TYRA Nasdaq
- ABSI Nasdaq
- Market Cap
- TYRA 422.6M
- ABSI 353.8M
- IPO Year
- TYRA 2021
- ABSI 2021
- Fundamental
- Price
- TYRA $8.92
- ABSI $3.09
- Analyst Decision
- TYRA Strong Buy
- ABSI Strong Buy
- Analyst Count
- TYRA 6
- ABSI 5
- Target Price
- TYRA $30.50
- ABSI $8.40
- AVG Volume (30 Days)
- TYRA 353.6K
- ABSI 3.4M
- Earning Date
- TYRA 05-08-2025
- ABSI 05-13-2025
- Dividend Yield
- TYRA N/A
- ABSI N/A
- EPS Growth
- TYRA N/A
- ABSI N/A
- EPS
- TYRA N/A
- ABSI N/A
- Revenue
- TYRA N/A
- ABSI $4,534,000.00
- Revenue This Year
- TYRA N/A
- ABSI $156.33
- Revenue Next Year
- TYRA N/A
- ABSI $93.61
- P/E Ratio
- TYRA N/A
- ABSI N/A
- Revenue Growth
- TYRA N/A
- ABSI N/A
- 52 Week Low
- TYRA $6.42
- ABSI $2.01
- 52 Week High
- TYRA $29.60
- ABSI $6.33
- Technical
- Relative Strength Index (RSI)
- TYRA 45.95
- ABSI 54.32
- Support Level
- TYRA $8.23
- ABSI $2.95
- Resistance Level
- TYRA $8.80
- ABSI $3.30
- Average True Range (ATR)
- TYRA 0.70
- ABSI 0.28
- MACD
- TYRA 0.19
- ABSI 0.12
- Stochastic Oscillator
- TYRA 75.30
- ABSI 83.85
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.